Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/166 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME14698647
PMID: | 14698647
LR: | 20041117
CED: | 20031230
DCO: | 20040317
Autoren: | Altman RD
Titel: | Measurement of structure (disease) modification in osteoarthritis.
Quelle: | Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society; VOL: 12 Suppl A; p. S69-76 /2004/
PM: | Print
SU: | IM
Sprache: | English
CY: | England
JID: | 9305697
ISSN: | 1063-4584
Institution: | Professor of Medicine, University of Miami, Miami, Florida 33125, USA. journals@royaltman.com
DT: | Journal Article
Schlagwörter
CT: | ANTIRHEUMATIC AGENTS/*therapeutic use; CLINICAL TRIALS/methods; DISEASE PROGRESSION; HUMANS; OSTEOARTHRITIS/*drug therapy; OSTEOARTHRITIS/radiography; RESEARCH DESIGN; TREATMENT OUTCOME
CTG: | ANTIRHEUMATIKA/*therapeutische Anwendung; KLINISCHE STUDIEN/Methoden; KRANKHEITSPROGRESSION; MENSCH; OSTEOARTHROSE/*Arzneimitteltherapie; OSTEOARTHROSE/Röntgenuntersuchung; FORSCHUNGSDESIGN; BEHANDLUNGSERGEBNIS
TE: | Antirheumatic Agents
AB: | Osteoarthritis (OA) research is beginning to focus on developing structure (disease) modifying treatments that will stabilize or reverse morphological changes, thereby altering the underlying pathologic process. The ability of anti-arthritic agents to modify the course of disease has been investigated in a limited number of clinical trials. Agents studied in published clinical trials include glycosaminoglycan-peptide complex (GP-C), glycosaminoglycan polysulfate (GAGPS), diacerein, and glucosamine sulphate. These clinical trials have been difficult to interpret and compare because the patients studied are often inadequately characterized or are not comparable across studies. Studies also vary with respect to the outcome measures analyzed and the methodology applied to measurement and data analysis. Further, in general, the rate of radiographic progression of OA is slow and is not consistent across populations and patients with varying disease severity. In man, the radiograph has been the gold standard for evaluating treatments. Further longitudinal validation of the radiograph is needed. As techniques improve, variation in the system and the number of patients needed in studies are decreasing. It may be that the radiograph will not achieve the needed degree of validation and will be supplanted by magnetic resonance imaging as the surrogate marker of joint status.

» Volltext »
» Fenster schließen »